Memory Digest

Why Some People With the Biggest Alzheimer's Risk Gene Stay Sharp

Tuesday, October 20, 2026

If you've ever had genetic testing, or have a parent with Alzheimer's, you may have heard of APOE4. It's the strongest common genetic risk factor for late-onset Alzheimer's disease, and roughly one in five people carry at least one copy. But carrying it is not destiny. Plenty of APOE4 carriers live into their 80s and 90s with sharp memories. A new study helps explain one reason why.

What the researchers found. A team at Columbia University had already discovered that some APOE4 carriers who stay healthy also carry a rare, protective change in a gene called FN1, which makes a protein called fibronectin. Fibronectin helps hold tissues together, but in people with APOE4 it can pile up around the brain's blood vessels. In their new study, published in Nature Aging, the researchers showed how that buildup does harm. Using human brain tissue and spinal fluid, stem-cell models, zebrafish and mice, they found that APOE4 drives extra fibronectin around blood vessels. Mice carrying human APOE4 had nearly twice as much of it as mice with the more common APOE3 version, and their blood-brain barrier, the tightly sealed lining that controls what gets from the blood into the brain, had become leaky. When the team raised fibronectin in support cells called astrocytes, the barrier leaked. When they lowered it, the barrier worked better. The rare protective FN1 variant appears to limit this buildup. (Sources: Columbia University Irving Medical Center news release via ScienceDaily, October 19; study in Nature Aging.)

What it does not mean. This is laboratory and animal research. There's no fibronectin-blocking treatment, and the researchers caution that any future drug would have to be designed carefully, because fibronectin also does important jobs like helping wounds heal. There's no test you can ask your doctor for to check for the protective variant, either. What the study does offer is a clearer picture of a new target, and a reminder that the health of the brain's blood vessels is a big part of the Alzheimer's story, especially for APOE4 carriers.

Why it's encouraging. For years, most Alzheimer's drug research focused on amyloid plaques. Studies like this one open other doors, such as protecting blood vessels early, before much damage is done. If you're curious about your own genes, our guide to genetic testing and APOE4 explains what a result can and can't tell you and why talking with a genetic counselor first is wise. For the bigger picture, see amyloid and tau explained and the 14 risk factors you can work on.

Thanks for reading, and have a good Tuesday. We'll see you tomorrow.